Development

Articles

Takeda has exercised an option to co-develop and co-commercialize an investigational, brain-penetrant progranulin replacement therapy for the potential treatment of frontotemporal dementia-granulin.

Denali Therapeutics and Takeda to Jointly Develop and Commercialize Investigational Treatment for FTD-GRN

Jennifer Markarian is manufacturing editor of BioPharm International.

Mechanistic models provide process understanding for developing robust manufacturing processes and for scale up and tech transfer.

Using Digital Twins to Model Process Chromatography

Corning’s new Ascent fixed bed reactor (FBR) system is an automated bioproduction platform designed to significantly improve yields and reduce bioproduction costs.

Corning’s New Cell and Gene Therapy Platform Demonstrates Large-Scale Bioproduction

AGC Biologics has acquired Novartis’ Longmont, Colorado, manufacturing facility for the commercial production of cell and gene therapies.

AGC Biologics Acquires Cell and Gene Therapy Commercial Manufacturing Facility

Cellares has entered into a strategic relationship with Poseida Therapeutics to advance a closed, automated, and scalable cell therapy manufacturing system.

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

Sparx Therapeutics will build its first commercial manufacturing facility in Yangzhou, China, for antibody drug production.

Sparx Therapeutics to Build Commercial Antibody Manufacturing Facility in China

VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.

VIVEbiotech Launches Lentiviral Vector Manufacturing Plant for Cell and Gene Therapies

Joshua Arias, joshua.arias@milliporesigma.com, is technical leader, BioReliance End to End Solutions, MilliporeSigma.

Mani Vinay Kumar Kotipalli is process engineer, Drug Substance Technology & Engineering, Amgen.

A unified scale-up approach, as presented here, can be applied to any unit operation.

A Unified Approach for Scaling Bioprocess Unit Operations

Using rDNA technology to synthesize production of proteins and peptide hormones, the biotech startup has achieved synthetic production of insulin, potentially lowering insulin cost by 30%. 

rBIO Hits Key Lab Milestone with Synthetic Production of Insulin

Feliza Mirasol is the science editor for 

Scaling needs for potential COVID-19 vaccines depend not only on capacity, but also on supply chain challenges and technological hurdles.

Scale Up